Tickers

1. Composite Trajectory Verdict

For a BDC lending business, the income statement (net investment income) and balance sheet (net asset value, asset quality) carry the most weight, while cash flow is secondary but relevant for distribution capacity.

Composite Trajectory: Deteriorating

The annual results for FY2025 versus FY2024 show deterioration across all three statements: a net loss from continuing operations of $(20.7) million versus $13.9 million income (10-K 2025-12-31, Consolidated Statements of Operations), operating cash flow down 39% to $11.2 million (10-K 2025-12-31, Consolidated Statements of Cash Flows), and book value per share falling 17% to $7.46 (10-K 2025-12-31, MD&A). The CECL reserve rose to 18.2% of carrying-value loans (10-K 2025-12-31, Consolidated Balance Sheets). Quarterly results post-BDC conversion (Q2 2026) show a net increase in net assets of $16.8 million and NAV per share of $8.25 (10-Q 2026-06-30, Consolidated Statements of Operations and Balance Sheets), but the filing explicitly states these are not comparable to prior periods due to ASC 946 adoption (10-Q 2026-06-30, MD&A). With no comparable quarterly trend and the most recent comparable annual period deteriorating, the composite trajectory is deteriorating.

2. Red Flags

• Net loss swing: FY2025 net loss from continuing operations $(20.7) million vs FY2024 net income $13.9 million (10-K 2025-12-31, Consolidated Statements of Operations).
• CECL provision surge: Provision for current expected credit losses jumped to $22.6 million in FY2025 from $4.2 million in FY2024; reserve reached $46.1 million (18.2% of carrying-value loans) vs $30.4 million (10.4%) (10-K 2025-12-31, Consolidated Statements of Operations and Balance Sheets).
• Nonaccrual concentration: As of June 30, 2026, 35.7% of amortized cost (22.7% of fair value) was on nonaccrual status across three loans (10-Q 2026-06-30, Portfolio Asset Quality).
• Distributable earnings collapse: Non-GAAP distributable earnings fell 75% to $8.7 million ($0.39/share) in FY2025 from $34.9 million ($1.68/share) in FY2024 (10-K 2025-12-31, MD&A Key Financial Measures).
• Dividend cut: Cash dividends declared per share dropped to $0.53 in FY2025 from $1.77 in FY2024 (10-K 2025-12-31, MD&A Dividends Declared Per Share).
• Book value erosion: Book value per share declined to $7.46 at Dec 31, 2025 from $9.02 at Dec 31, 2024 (10-K 2025-12-31, MD&A).
• Cash drain: Unrestricted cash fell to $38.6 million at Dec 31, 2025 from $103.6 million at Dec 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets).
• Leverage increase post-conversion: Aggregate principal debt outstanding rose to $207 million at June 30, 2026 from $98 million at Dec 31, 2025; asset coverage ratio fell to 190% from 278% (10-Q 2026-06-30, Liquidity and Capital Resources).
• Legal overhang: Multiple ongoing litigations with Private Company G and related parties, with no reasonable estimate of outcomes (10-K 2025-12-31, MD&A Developments During the Year Ended December 31, 2025).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: FY2025 net loss from continuing operations was $(20.7) million versus $13.9 million net income in FY2024 (10-K 2025-12-31, Consolidated Statements of Operations). Interest income declined 39.8% to $31.3 million from $52.0 million, driven by loan exits, lower deployed capital, and $8.3 million less interest from nonaccrual loans (10-K 2025-12-31, MD&A). The CECL provision surged to $22.6 million from $4.2 million (10-K 2025-12-31, Consolidated Statements of Operations). Non-GAAP distributable earnings fell 75% to $8.7 million ($0.39/share) from $34.9 million ($1.68/share) (10-K 2025-12-31, MD&A). For the six months ended June 30, 2026, the company reported a net increase in net assets from operations of $16.8 million under ASC 946 (10-Q 2026-06-30, Consolidated Statements of Operations), but the filing states these results are not comparable to the prior-year period due to the accounting change (10-Q 2026-06-30, MD&A). With only two comparable annual periods showing clear deterioration, the earnings trajectory is deteriorating.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash provided by operating activities (continuing) decreased to $11.2 million in FY2025 from $18.3 million in FY2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Net cash from investing activities (continuing) fell to $34.9 million from $42.4 million, primarily due to a $96.1 million drop in loan sale proceeds partially offset by lower fundings and higher repayments (10-K 2025-12-31, MD&A). Net cash used in financing activities (continuing) widened to $(111.1) million from $(34.7) million, driven by a $193.4 million net reduction in borrowings and the absence of the prior year's $67.9 million spin-off distribution (10-K 2025-12-31, Consolidated Statements of Cash Flows). The cash balance dropped to $38.6 million at Dec 31, 2025 from $103.6 million at Dec 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets). Quarterly cash flow statements for 2026 are not provided in the 10-Q excerpt, so no comparable quarterly trend can be assessed.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets contracted 31% to $275.6 million at Dec 31, 2025 from $402.1 million at Dec 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets). Shareholders' equity declined 13% to $175.6 million from $201.4 million, with book value per share falling to $7.46 from $9.02 (10-K 2025-12-31, Consolidated Balance Sheets and MD&A). The CECL reserve increased to $46.1 million (18.2% of carrying-value loans) from $30.4 million (10.4%) (10-K 2025-12-31, Consolidated Balance Sheets). Three loans with $88.8 million carrying value were on nonaccrual status at Dec 31, 2025 (10-K 2025-12-31, Consolidated Balance Sheets). At June 30, 2026, total assets were $399.7 million and NAV per share was $8.25 (10-Q 2026-06-30, Consolidated Balance Sheets), but the balance sheet is prepared under ASC 946 and is not comparable to the Dec 31, 2025 presentation (10-Q 2026-06-30, MD&A). Based on the comparable annual periods, the balance sheet trajectory is deteriorating.

6. Data Gaps

• Quarterly cash flow statements for Q2 2026 and Q2 2025 (not included in the 10-Q 2026-06-30 excerpt).
• Q1 2026 vs Q1 2025 income statement, balance sheet, and cash flow (10-Q 2026-03-31 referenced but not provided in the filings).
• Full-year 2026 results (not yet filed).
• Comparable post-conversion quarterly trends (need Q2 2027 vs Q2 2026 under consistent ASC 946).
• Detailed breakdown of the $1.8 million "other income" in six months ended June 30, 2026 (described as fees from loan exits but not fully quantified per loan).
• Granular loan-level performance data for the 17 investments held at June 30, 2026 beyond the risk rating summary.